1978 W Winton Ave
Be part of pandemic-speed manufacturing for medicines
Talent is, and will always be, at the heart of our business. As part of our long-term growth strategy, we plan for significant expansion in Hayward, CA over the next 3 years. We are looking for talent to join us in various positions such as Quality Assurance, Operations, Regulatory, Engineering, Program Management, and many more.
We are one of the world's leading and most trusted suppliers to the pharmaceutical and biotech markets. We continue to break new ground within our industry, attracting global clients to our Hayward site. Rooted in the Bay Area and close to innovation in vaccines and therapeutics, we provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs and through to commercial launch. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world class manufacturing and process excellence.
With a history that dates back to 1897, Lonza is a trusted name with a wealth of knowledge and expertise in life science. Today we are more than 15,000 employees in more than 100 locations around the world. Together in 2019, we supported the development and production of over 1000 therapies.
We offer you exposure to upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow. While other companies may only offer you the opportunity to work on a few treatments, at Lonza you will be working on scores of treatments per year for a variety of customers.
We are here to make a meaningful difference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming it. What we do today is helping to create a healthier, happier world tomorrow. That’s the meaningful difference we make every day.
211 articles with Lonza
Lonza Publishes IFRS 15 Adoption and Pro-Forma Numbers for Full-Year 2017 for Its Continuing Operations, Excluding Water Care Business
Lonza today is publishing unaudited Full-Year 2017 information excluding the Water Care business and taking into consideration additional reporting-related items to enable comparison and inform capital market participants about the upcoming reporting changes prior to our Full-Year 2018 results publication.
ERS Genomics Limited and Lonza Pharma & Biotech announced today a license agreement to provide Lonza with access to ERS Genomics’ CRISPR/Cas9 genome editing technology patents.
New biologics facility, scheduled to be operational in 2020, will provide development and manufacturing facilities from early- to late-clinical and early-commercial stages
Lonza Further Strengthens Focus on Its Healthcare Continuum Strategy by Signing Agreement to Divest Water Care Business to Platinum Equity
Lonza and Platinum Equity jointly announced today that Platinum Equity has entered into a definitive agreement with Lonza to acquire Lonza's Water Care business and operations for USD 630 million.
Lonza Acquires a Controlling Stake in Octane Biotech to Further Develop CocoonTM Autologous Technology
Acquisition further strengthens Lonza’s commitment to drive the next generation of manufacturing patient-specific and personalized therapies
Lonza Continues Strong Momentum in Businesses Along the Healthcare Continuum in Q3 2018 and Confirms Positive Outlook for the Full Year
Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offerings – continued to drive growth
Lonza is holding a series of events as part of this year's Capital Markets Day from 24-26 September in Zurich and Visp (CH).
CHF 400 million investment in Lonza's biopark in Visp (CH) to expand IbexTM Solutions with two innovative offerings
CHF 400 million investment in Lonza's biopark in Visp (CH) to expand Ibex™ Solutions with two innovative offerings
Akouos, based in Boston, announced a Series A financing worth $50 million. The round was led by seed investors 5AM Ventures and New Enterprise Associates (NEA).
Lonza Bioscience is inviting visitors to explore its new dedicated website: bioscience.lonza.com.
Lonza and Innosieve Diagnostics Announce Exclusive Distribution Agreement for Rapid Bioburden Testing Technology
Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology.
Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.
Lonza to Host New Webinar: “CRISPR – Tips and Tricks for Efficient Delivery into Primary Cells and Cell Lines”
Lonza is hosting a free 60-minute webinar on the CRISPR/Cas9 genome editing method.
Proteon Therapeutics, Inc. announced a long-term contract extension with Lonza Pharma & Biotech for the commercial supply of investigational vonapanitase’s active pharmaceutical ingredient (API).
Synpromics awarded Innovate UK grant to evaluate its inducible promoter platform in collaboration with Lonza Pharma & Biotech
Synpromics Ltd announces a partnership with Lonza Pharma & Biotech to further develop its inducible promoter system and improve manufacturing of biopharmaceuticals.
Lonza Opens World's Largest Dedicated Cell and-Gene-Therapy Manufacturing Facility in Pearland, Greater Houston, TX (USA)
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.
This new product offering from Lonza is a result of a worldwide marketing and distribution agreement with Kirkstall.
Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines
The agreement covers all stages of the development and manufacturing.